Ramaswamy notches his 5th biotech startup in 3 years after inking a deal with Merck for PhIII urology drug
Vivek Ramaswamy has launched another new biotech company.
Ramaswamy’s umbrella group Roivant Sciences notched its 5th “-vant” startup — Urovant Sciences — after bagging a Phase III-ready urology drug from Merck.
Talking from the tarmac as he was preparing to jet his way to Europe, the 30-something entrepreneur tells me you can now expect the business development team at Basel-based Roivant to go after more deals to beef up the pipeline — a strategy that has marked his first four company launches over just the last three years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.